Skip to main content
Log in

Prolonged-Release Oxycodone/Naloxone in Nonmalignant Pain: Single-Center Study in Patients with Constipation

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Opioid treatment for chronic malignant and nonmalignant pain of moderateto-severe intensity is associated with bowel dysfunction leading to constipation; this often requires opioid dose reduction or interruption. Combination opioid agonist/antagonist therapy can restore normal bowel function. A prolonged-released (PR) fixed-dose combination of oxycodone and naloxone has been developed and efficacy has been demonstrated in phase 3 clinical trials.

Methods

This 2-month, retrospective, singlecenter, observational study assessed the effectiveness and safety of PR oxycodone/naloxone in consecutive nononcological patients with constipation and chronic pain despite analgesic treatment; specific subgroup analyses were performed in opioid-experienced or opioid-naïve patients and in age subgroups. Efficacy was assessed by: intensity of pain; bowel function; effective oxycodone/naloxone dose; Patients’ Global Impression of Change (PGIC) scale; rescue paracetamol; and laxative use. Safety evaluations were also performed.

Results

Of 1,051 patients starting on the oxycodone/naloxone combination (32.0% male; mean age 67 ± 13 years, 53.9% opioid naïve), 1,012 completed 2 months of treatment. Overall, PR oxycodone/naloxone was associated with a significant decrease in pain intensity (P < 0.001), a reduced need for rescue paracetamol (P < 0.001), and PGIC score of “very much improved” or “much improved” in 84.0% of patients. Constipation markedly decreased (P < 0.001) despite reduced laxative use (P < 0.001 vs. baseline). The most frequent treatment-emergent adverse events were somnolence (2.0%), dizziness (1.1%), and confusion (1.0%). Clinical differences in endpoints were seen between opioid-naïve and opioid-experienced patients, and among agestratified groups, but efficacy was similar to the overall population.

Conclusions

Fixed combination PR oxycodone/naloxone was effective and well tolerated in moderate-to-severe chronic pain in patients with constipation, providing analgesia and relief from bowel dysfunction. Consistent efficacy across patient subgroups provides guidance for daily management of chronic pain when therapy options are limited due to bowel dysfunction, regardless of age or previous medication. Supplementary material belonging to this paper is available on SpringerLink.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287–333.

    Article  PubMed  Google Scholar 

  2. Dunlop W, Uhl R, Khan I, Taylor A, Barton G. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ. 2012;15:564–575.

    Article  PubMed  Google Scholar 

  3. Trescot AM. Review of the role of opioids in cancer pain. J Natl Compr Canc Netw. 2010;8:1087–1094.

    PubMed  CAS  Google Scholar 

  4. Coluzzi F, Pappagallo M. National Initiative On Pain Control. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol. 2005;71:425–433.

    PubMed  CAS  Google Scholar 

  5. Rosti G, Gatti A, Costantini A, Sabato AF, Zucco F. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci. 2010;14:1045–1050.

    PubMed  CAS  Google Scholar 

  6. Gatti A, Sabato AF. Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone. Clin Drug Invest. 2012;32:293–301.

    Article  CAS  Google Scholar 

  7. Schutter U, Grunert S, Meyer C, Schmidt T, Nolte T. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin. 2010;26:1377–1387.

    Article  PubMed  CAS  Google Scholar 

  8. Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther. 2012;50:360–367.

    PubMed  CAS  Google Scholar 

  9. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolongedrelease oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56–64.

    Article  PubMed  CAS  Google Scholar 

  10. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderateto-severe noncancer pain. Curr Med Res Opin. 2008;24:3503–3512.

    Article  PubMed  CAS  Google Scholar 

  11. Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe nonmalignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10:531–543.

    Article  PubMed  Google Scholar 

  12. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract. 2010;64:763–774.

    Article  PubMed  CAS  Google Scholar 

  13. Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol. 2010;10:12.

    Article  PubMed  Google Scholar 

  14. Clemens KE, Quednau I, Klaschik E. Bowel function during pain therapy with oxycodone/ naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract. 2011;65:472–478.

    Article  PubMed  CAS  Google Scholar 

  15. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, doubleblind, active-controlled, double-dummy, parallelgroup study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012;26:50–60.

    Article  PubMed  Google Scholar 

  16. Hermanns K, Junker U, Nolte T. Prolongedrelease oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study. Expert Opin Pharmacother. 2012;13:299–311.

    Article  PubMed  CAS  Google Scholar 

  17. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12:371–383.

    Article  PubMed  CAS  Google Scholar 

  18. Ueberall MA, Muller-Lissner S, Buschmann-Kramm C, Bosse B. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res. 2011;39:41–50.

    PubMed  CAS  Google Scholar 

  19. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(Suppl.):S11–S18.

    Article  Google Scholar 

  20. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–158.

    Article  PubMed  CAS  Google Scholar 

  21. Rentz AM, van Hanswijck de Jonge P, Leyendecker P, Hopp M. Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries. Curr Med Res Opin. 2011;27:35–44.

    Article  PubMed  CAS  Google Scholar 

  22. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9:1144–1154.

    Article  PubMed  CAS  Google Scholar 

  23. Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122:114–120.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marzia Lazzari.

Additional information

The original online version for this chapter can be found at www.advancesintherapy.com

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gatti, A., Casali, M., Lazzari, M. et al. Prolonged-Release Oxycodone/Naloxone in Nonmalignant Pain: Single-Center Study in Patients with Constipation. Adv Therapy 30, 41–59 (2013). https://doi.org/10.1007/s12325-012-0074-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-012-0074-0

Keywords

Navigation